目的 探討津力達顆粒聯(lián)合那格列奈治療2型糖尿病的臨床療效。方法 選取2017年4月-2019年5月在鄭州人民醫(yī)院治療的2型糖尿病患者128例，隨機分為對照組和治療組，每組各64例。對照組餐前口服那格列奈片，120 mg/次，3次/d。治療組在對照組的基礎上口服津力達顆粒，1袋/次，3次/d；兩組患者均治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者空腹血糖（FPG）、餐后兩小時血糖（2 h PG）、糖化血紅蛋白（HbA1c）、總膽固醇（TC）、三酰甘油（TG）、高密度脂質(zhì)蛋白（HDL-C）、低密度脂質(zhì)蛋白（LDL-C）、白細胞介素6（IL-6）、丙二醇（MDA）、超氧化物歧化酶（SOD）、高敏C反應蛋白（hs-CRP）、胰島素抵抗指數(shù)（HOMA-IR）、胰島素β細胞指數(shù)（HOMA-β）。結果 治療后，治療組總有效率為96.88%，高于對照組總有效率的76.56%（P<0.05）。治療后，兩組FPG、2 h PG、HbA1c、TC、TG、LDL-C、IL-6、MDA、hs-CRP、HOMA-IR均顯著降低，但HDL-C、SOD、HOMA-β顯著升高（P<0.05）。治療后，治療組患者FPG、2 h PG、HbA1c、TC、TG、LDL-C、IL-6、MDA、hs-CRP、HOMA-IR指標均顯著低于對照組患者（P<0.05），但HDL-C、SOD、HOMA-β指標顯著高于對照組（P<0.05）。結論 津力達顆粒聯(lián)合那格列奈治療2型糖尿病能有效降低血糖，改善臨床癥狀、血脂與胰腺β細胞水平，藥物不良反應較少。

Objective To explore the clinical effect of Jinlida Granules combined with nateglinide in treatment of type 2 diabetes. Methods Patients (128) with type 2 diabetes in Zhengzhou People's Hospital from April 2017 to May 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients in the control group were po administered with Nateglinide Tablets, 120 mg/time, three times daily. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the FPG, 2 h PG, HbA1c, TC, TG, HDL-C, LDL-C, IL-6, MDA, SOD, hs-CRP, HOMA-IR, and HOMA-β in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 96.88%, which was higher than 76.56% of the control group (P<0.05). After treatment, FPG, 2 h PG, HbA1c, TC, TG, LDL-C, IL-6, MDA, hs-CRP and HOMA-IR in two groups were significantly decreased, but HDL-C, SOD, and HOMA-β were significantly increased (P<0.05). After treatment, FPG, 2 h PG, HbA1c, TC, TG, LDL-C, IL-6, MDA, hs-CRP and HOMA-IR in the treatment group were significantly lower than those in the control group, while the indexes of HDL-C, SOD, and HOMA-β in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Jinlida Granules combined with nateglinide in the treatment of type 2 diabetes can effectively reduce blood glucose, improve clinical symptoms, blood lipids and pancreatic β-cell levels, and have less adverse drug reactions.

R977

河南省科技攻關項目（182102310224）